Despite being used off-label to treat nausea and vomiting in pregnancy, the FDA warns against
There might be better options Widespread or long-term use of drugs by patients may uncover side effects not discovered during the clinical trials a drug company did to get FDA approval of the medicine
Each 4-mg ZOFRAN Tablet for oral administration contains ondansetron HCl dihydrate equivalent to 4 mg of ondansetron
12 to 17 years of age: 8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8-mg dose 8 hours after the first dose
The active ingredient in ZOFRAN ODT orally disintegrating tablets is ondansetron base, the racemic form of ondansetron, and
An age-appropriate formulation must be developed for younger pediatric patients
mil
Zofran Oral Solution, a selective 5-HT3 receptor FDA Pediatric Safety Communications
FDA alerts health care providers about Please refer to your supplemental new drug applications (sNDA) dated, June 4, 2020, received June 4, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zofran (ondansetron hydrochloride) tablets, Zofran (ondansetron hydrochloride) oral solution, and Zofran ODT
It was designed originally for chemotherapy-induced nausea and vomiting